Search

Your search keyword '"Hamzeh-Cognasse Hind"' showing total 390 results

Search Constraints

Start Over You searched for: Author "Hamzeh-Cognasse Hind" Remove constraint Author: "Hamzeh-Cognasse Hind"
390 results on '"Hamzeh-Cognasse Hind"'

Search Results

7. Direct contact of platelets and their released products exert different effects on human dendritic cell maturation

8. Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study

10. Immunoregulatory molecule expression on extracellular microvesicles in people living with HIV

13. P-202 Evaluation de l[StQuote]efficacité des transfusions des concentrés plaquettaires traités par Amotosalen/UVA en chirurgie cardiaque

14. P-052 Étude pilote sur les mélanges de plasma isogroupe ABO ou universels avec ou sans traitement de réduction des agents pathogènes

15. P-228 Les modèles mathématiques peuvent prédire l[StQuote]activité des plaquettes humaines et les expressions protéiques en réponse à diverses stimulations

20. The efficacy of therapeutic plasma exchange in COVID-19 patients on endothelial tightness in vitro is hindered by platelet activation

21. <scp>DAMPS</scp> and complement activation in platelet concentrates that induce adverse reactions in patients

22. Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion

25. Quality assessment of red blood cell concentrates from blood donors at the extremes of the age spectrum: The BEST collaborative study.

28. Autoantibodies against type I IFNs in patients with critical influenza pneumonia

31. Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology

33. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation

36. Assessment of the soluble proteins HMGB1, CD40L and CD62P during various platelet preparation processes and the storage of platelet concentrates: The BEST collaborative study

39. Platelets as Key Factors in Inflammation: Focus on CD40L/CD40

40. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies

41. Platelet concentrates in platelet additive solutions generate less complement activation products during storage than platelets stored in plasma

43. Inflammatory Markers and Auto-Abs to Type I IFNs in COVID-19 Convalescent Plasma

44. Platelet EVs contain an active proteasome involved in protein processing for antigen presentation via MHC-I molecules

46. Les vésicules extracellulaires dérivées des plaquettes sont impliquées dans la présentation des antigènes via leur MHC de classe I

48. Concentrés plaquettaires (surnageants), réactions post-transfusionnelles, temps de stockage : analyse protéomique

49. Réactions post-transfusionnelles, concentrés plaquettaires (culots/surnageants), stockage : étude protéomique

50. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Catalog

Books, media, physical & digital resources